Association between stress hyperglycemia ratio index and all-cause mortality in critically ill patients with atrial fibrillation: a retrospective study using the MIMIC-IV database.

Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE

Original Publication: London : BioMed Central, [2002-

Atrial Fibrillation*/mortality ; Atrial Fibrillation*/blood ; Atrial Fibrillation*/diagnosis ; Biomarkers*/blood ; Blood Glucose*/metabolism ; Cause of Death* ; Critical Illness*/mortality ; Databases, Factual* ; Hyperglycemia*/mortality ; Hyperglycemia*/blood ; Hyperglycemia*/diagnosis; Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Intensive Care Units ; Predictive Value of Tests ; Prognosis ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Time Factors

Background: The stress hyperglycemia ratio (SHR) was developed to mitigate the influence of long-term chronic glycemic factors on stress hyperglycemia levels, which are associated with adverse clinical events, particularly cardiovascular events. However, studies examining the SHR index and its prognostic significance in patients with atrial fibrillation (AF) are lacking. This study aims to evaluate the relationship between the SHR index and all-cause mortality in critically ill patients with AF upon Intensive Care Unit admission.
Methods: The patients' data were extracted from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. All patients were categorized into four groups based on the SHR index. The outcomes include both primary and secondary endpoints, with the primary endpoints being 30-day and 365-day all-cause mortality, and the secondary endpoints being 90-day and 180-day all-cause mortality. The SHR index was analyzed using quartiles, and the Kaplan-Meier curve was employed to compare the outcomes across groups. Cox proportional-hazards regression and restricted cubic splines (RCS) were used to assess the relationship between the SHR index and the outcomes.
Results: Out of a total of 1,685 participants, the average age was 63.12 years (range: 40.17 to 101.49), with 1,004 (59.58%) being male. Higher levels of the SHR index were associated with an increased risk of all-cause mortality at 30 days, 90 days, 180 days, and 365 days, as indicated by the Kaplan-Meier curves (log-rank P < 0.01). Additionally, Cox proportional-hazards regression analysis revealed that the risk of mortality at these time points was significantly higher in the highest quartile of the SHR index. Restricted cubic splines (RCS) analysis demonstrated U-shaped relationships between the SHR index and all-cause mortality, with inflection points at 0.73 for 30-day mortality and 0.76 for 365-day mortality. Compared to patients with SHR levels below these inflection points, those with higher levels had a 69.9% increased risk for 30-day all-cause mortality (hazard ratio [HR] 1.699; 95% confidence interval [CI] 1.336 to 2.159) and a 61.6% increased risk for 365-day all-cause mortality (HR 1.616; 95% CI 1.345 to 1.942).
Conclusion: In critically ill patients with AF, higher levels of the SHR index are significantly associated with an increased risk of all-cause mortality at 30 days, 90 days, 180 days, and 365 days. The SHR index may serve as a valid indicator for assessing the severity and guiding the treatment of AF patients in the ICU.
(© 2024. The Author(s).)

Int J Environ Res Public Health. 2017 Sep 30;14(10):. (PMID: 28974008)
Cardiovasc Diabetol. 2023 Jul 4;22(1):165. (PMID: 37403082)
J Thorac Dis. 2020 Nov;12(11):6598-6608. (PMID: 33282361)
Am Fam Physician. 2017 Nov 15;96(10):648-654. (PMID: 29431385)
JAMA. 2006 Apr 12;295(14):1681-7. (PMID: 16609090)
Cardiovasc Diabetol. 2017 Jul 6;16(1):86. (PMID: 28683829)
Circulation. 2014 Feb 25;129(8):837-47. (PMID: 24345399)
Bull Exp Biol Med. 2005 Oct;140(4):397-9. (PMID: 16671563)
Ann Surg. 2012 Sep;256(3):446-52. (PMID: 22868366)
Cardiovasc Diabetol. 2021 Oct 19;20(1):211. (PMID: 34666746)
Diabetes Care. 2002 Dec;25(12):2123-8. (PMID: 12453948)
Med Sci Monit. 2018 Apr 11;24:2164-2172. (PMID: 29641513)
Cardiovasc Diabetol. 2023 Feb 8;22(1):29. (PMID: 36755256)
Intensive Care Med. 2019 Jul;45(7):928-938. (PMID: 31089761)
Int J Mol Sci. 2022 Jul 27;23(15):. (PMID: 35955426)
Redox Biol. 2019 Jan;20:247-260. (PMID: 30384259)
Angiology. 2024 Aug;75(7):645-650. (PMID: 37005730)
Cardiovasc Diabetol. 2022 Mar 29;21(1):48. (PMID: 35351149)
J Thromb Haemost. 2004 Aug;2(8):1282-91. (PMID: 15304032)
J Am Heart Assoc. 2019 Feb 19;8(4):e011295. (PMID: 30776949)
J Clin Endocrinol Metab. 2015 Dec;100(12):4490-7. (PMID: 26485219)
Cardiovasc Diabetol. 2023 Jul 15;22(1):180. (PMID: 37454147)
Front Endocrinol (Lausanne). 2023 Apr 03;14:1111026. (PMID: 37077351)
Front Aging Neurosci. 2022 Sep 01;14:936862. (PMID: 36118702)
Circ Res. 2014 Apr 25;114(9):1500-15. (PMID: 24763467)
Metabolism. 2021 Jun;119:154766. (PMID: 33766485)
Nutrients. 2020 Oct 03;12(10):. (PMID: 33023000)
Cardiovasc Diabetol. 2023 Mar 31;22(1):76. (PMID: 37004002)
Diabetes Care. 2001 Aug;24(8):1476-85. (PMID: 11473089)
Clin Cardiol. 2013 Nov;36(11):654-62. (PMID: 23788255)
Trends Endocrinol Metab. 2020 Feb;31(2):118-130. (PMID: 31690508)
J Am Coll Cardiol. 2007 Jan 23;49(3):304-10. (PMID: 17239711)
Eur Heart J. 2021 Feb 1;42(5):373-498. (PMID: 32860505)
Diabetes Care. 2022 Apr 1;45(4):947-956. (PMID: 35045167)
Metabolism. 2009 Jan;58(1):102-8. (PMID: 19059537)
J Thromb Haemost. 2010 Aug;8(8):1663-9. (PMID: 20492456)
Ann Intern Med. 2023 Jul;176(7):ITC97-ITC112. (PMID: 37429028)
Clin Microbiol Infect. 2018 Jan;24(1):10-15. (PMID: 28082192)
Cardiovasc Diabetol. 2023 Oct 21;22(1):281. (PMID: 37865764)
Eur Heart J. 2014 Jun 7;35(22):1448-56. (PMID: 24536084)
Int J Mol Sci. 2019 Jul 02;20(13):. (PMID: 31269778)
Lancet. 2009 May 23;373(9677):1798-807. (PMID: 19465235)
Eur Heart J. 2004 Jul;25(14):1242-8. (PMID: 15246643)
Nat Rev Dis Primers. 2016 Mar 31;2:16016. (PMID: 27159789)
J Clin Endocrinol Metab. 1981 Jun;52(6):1235-41. (PMID: 7014600)
Cardiovasc Diabetol. 2023 Jul 26;22(1):189. (PMID: 37495967)

Keywords: All-cause mortality; Atrial fibrillation; Prognosis; Stress hyperglycemia ratio

0 (Biomarkers)
0 (Blood Glucose)

Date Created: 20241014 Date Completed: 20241015 Latest Revision: 20250318

20250318

PMC11476318

10.1186/s12933-024-02462-1

39402588